Core Viewpoint - Coeptis Therapeutics Holdings, Inc. has announced that its registration statement for a merger with Z Squared Inc. has been declared effective by the SEC, and it will begin mailing the definitive proxy statement/prospectus to stockholders ahead of the Stockholder Meeting scheduled for January 30, 2026 [1] Company Overview - Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [3] - The company operates through its subsidiaries, including Coeptis Pharmaceuticals, GEAR Therapeutics, SNAP Biosciences, and Coeptis Technologies [3] Therapeutic Portfolio - Coeptis's therapeutic portfolio includes assets licensed from Deverra Therapeutics, featuring an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage natural killer cell therapy technology [4] - The company is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh, alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and the Karolinska Institute [4] Technology Division - Coeptis has established a Technology Division aimed at enhancing operational capabilities through advanced technologies, including AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group [5] Z Squared Overview - Z Squared is focused on building a sustainable cryptocurrency mining operation, with 9,000 ASIC miners targeting Dogecoin and Litecoin, addressing market caps of $20 billion and $6 billion respectively [7] Stockholder Meeting - The Stockholder Meeting for the merger transaction will be held on January 30, 2026, with notices being mailed to stockholders of record as of January 2, 2026 [1]

Core Points - Coeptis Therapeutics Holdings, Inc. has extinguished its convertible note with YA II PN, Ltd, clearing its outstanding debt obligations to Yorkville [1][2] - The CEO stated that this action strengthens the company's capital structure and positions it well for long-term goals, including potential operations in the cryptocurrency space [2] - Coeptis focuses on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases through its subsidiaries [3][4] Company Overview - Coeptis Therapeutics Holdings includes subsidiaries such as Coeptis Pharmaceuticals, GEAR Therapeutics, SNAP Biosciences, and Coeptis Technologies, emphasizing biopharmaceutical and technology advancements [3] - The therapeutic portfolio includes assets licensed from Deverra Therapeutics, featuring an allogeneic cellular immunotherapy platform and clinical-stage NK cell therapy technology [4] - Coeptis is also developing a universal, multi-antigen CAR technology in collaboration with the University of Pittsburgh and other distinguished medical researchers [4] Technology Division - Coeptis has established a Technology Division aimed at enhancing operational capabilities through advanced technologies, including AI-powered marketing software and robotic process automation tools [5] - These technologies are intended to optimize business processes and improve overall efficiency [5] Compliance and Standards - The company is headquartered in Wexford, PA, and is committed to advancing its mission within the regulatory framework set by the FDA, ensuring compliance and high standards of patient care [6]

Company Overview - Coeptis Therapeutics Holdings, Inc. is a next-generation technology and biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [3][4] - The company has a therapeutic portfolio that includes assets licensed from Deverra Therapeutics, featuring an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage natural killer cell therapy technology [4] - Coeptis is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh, alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and the Karolinska Institute [4] Recent Developments - Coeptis has filed a registration statement on Form S-4 with the SEC related to a proposed merger agreement with Z Squared Inc. [1][2] - The Form S-4 includes a preliminary proxy statement/prospectus regarding the proposed transaction, which has not yet become effective [2] Technology Division - Coeptis has established a Technology Division aimed at enhancing operational capabilities through advanced technologies, including AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group [5] Z Squared Overview - Z Squared Inc. is focused on digital asset compute mining, primarily generating Dogecoin (DOGE) and other digital assets like Litecoin, with a market cap of $20 billion [7]